C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
INCR Equity

InterCure

OTCMKTS · INCR

$5.43
+3.62%
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 3/5
40/100 composite
Fundamentals50
Regulatory55
Market15
Editorial30
Composite · trailing 12 months

Intercure Ltd. earns a Neutral rating with 3/5 conviction, reflecting a 39.5 composite that lacks sufficient breadth for a more constructive stance. Regulatory is the strongest pillar at 55, supported by Israel’s 70-point jurisdiction posture and an 80 enforcement subscore. Fundamentals contribute 50, as strong top-line expansion is offset by weak profitability and a stretched financial condition. Editorial contributes 30, with no newsroom or brief activity to strengthen the signal. Market contributes only 15 because reported trading volume provides no liquidity support. The resulting profile combines credible jurisdictional standing with limited market confirmation and material financial pressure.

Revenue increased 23.9% year over year, producing a 73.9 growth subscore, but gross margin remained only 16.7% and the gross-margin subscore stood at 27.8. Operating margin was reported at zero, while net income remained negative by approximately 32.1 million and EBITDA was negative by roughly 55.3 million. A cash-burn ratio near one and a 15 cash-runway subscore reinforce the stretched classification; positive revenue momentum does not counter the bottom-line loss or negative EBITDA. Filing cadence is also thin. The latest primary regulatory filing was dated June 22, 2026, with no regulatory events recorded during the latest 90 days and two across 180 days, resulting in a 25 cadence subscore. These observations draw on primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage.

The clearest catalyst sits within the regulatory pillar. Israel’s favorable jurisdiction score and the absence of enforcement hits preserve the company’s strongest analytical foundation, while the low cadence score leaves room for measurable improvement. A fresh sequence of primary regulatory filings that documents operating progress, financial performance, and corporate developments would increase transparency and reinforce the regulatory contribution. That improvement carries greater rating relevance than editorial visibility because regulatory already leads the pillar set and has identifiable support from jurisdiction and enforcement. The single most important forward-looking signal to watch is a sustained acceleration in filing cadence after the June 2026 filing.

Scored: 2026-09-22Valid through: 2026-11-06Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
Headquarters
85 MEDINAT HA-YEHUDIM STREET, HERZLIYA, L3, 4676670
Phone
972774605012
CEO
Alexander Rabinovich
CFO
Amos Cohen
SEC CIK
1857030
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$55.4M
Enterprise value
$101.1M
Price to book
0.42
Price to sales
0.58
EV / EBITDA
5.29
Revenue (TTM)
$243.1M
Gross profit (TTM)
$40.6M
EBITDA
$-55.3M
Operating margin
0.0%
Profit margin
-13.2%
Rev growth YoY
23.9%
Return on equity
-9.3%
Return on assets
-5.8%
EPS (TTM)
$-0.22
Wall St. target price
$33.56
Shares outstanding
57.2M
Insider ownership
39.2%
Institutional ownership
1.0%
Beta
0.57
Full-time employees
285
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Annual report
Latest 10-K
Filing portal
TASE (Maya)
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for InterCure (INCR)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for InterCure (INCR), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

Analyst average price target $7.17.

CIN editorial stance: Event-Driven Opportunity. Setup improving. Confirmation still pending. (2 bullish signals, 0 bearish signals.)

Bullish and bearish analyst opinions for InterCure Ltd. (INCR)

Bullish view. InterCure Ltd. is the largest medical-cannabis distributor in Israel with steady script volume, and bulls treat it as the closest thing to a regulated pharma-cannabis pure-play.

Bearish view. Bearish coverage flags concentration in one market, currency volatility, and dependence on Israeli health-fund reimbursement policy.

Live ratings, price targets, and consensus figures for InterCure Ltd. appear above this summary. Explore analyst coverage across the 326-equity cannabis universe.

Latest price: $5.43 (+3.62%) on OTCMKTS.

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for INCR are maintained by Cannabis Investor News and refreshed throughout the trading day.